SG153874A1 - Neutralizing epitope-based growth enhancing vaccine - Google Patents
Neutralizing epitope-based growth enhancing vaccineInfo
- Publication number
- SG153874A1 SG153874A1 SG200904421-5A SG2009044215A SG153874A1 SG 153874 A1 SG153874 A1 SG 153874A1 SG 2009044215 A SG2009044215 A SG 2009044215A SG 153874 A1 SG153874 A1 SG 153874A1
- Authority
- SG
- Singapore
- Prior art keywords
- peptides
- fusion proteins
- new
- gdf8
- nucleic acids
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 6
- 102000037865 fusion proteins Human genes 0.000 abstract 4
- 108020001507 fusion proteins Proteins 0.000 abstract 4
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 abstract 3
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53371903P | 2003-12-31 | 2003-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG153874A1 true SG153874A1 (en) | 2009-07-29 |
Family
ID=34748944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200904421-5A SG153874A1 (en) | 2003-12-31 | 2004-12-21 | Neutralizing epitope-based growth enhancing vaccine |
Country Status (21)
Country | Link |
---|---|
US (3) | US7371726B2 (ru) |
EP (1) | EP1699820A2 (ru) |
JP (2) | JP2007535912A (ru) |
KR (1) | KR20060120229A (ru) |
CN (1) | CN1902221A (ru) |
AR (1) | AR047345A1 (ru) |
AU (1) | AU2004312411B8 (ru) |
BR (1) | BRPI0418317A (ru) |
CA (1) | CA2551877A1 (ru) |
EC (1) | ECSP066683A (ru) |
IL (1) | IL176494A0 (ru) |
MX (1) | MXPA06007514A (ru) |
NO (1) | NO20063478L (ru) |
NZ (1) | NZ547593A (ru) |
PE (1) | PE20051050A1 (ru) |
RU (1) | RU2422460C2 (ru) |
SG (1) | SG153874A1 (ru) |
TW (1) | TWI357906B (ru) |
UA (1) | UA93855C2 (ru) |
WO (1) | WO2005066204A2 (ru) |
ZA (1) | ZA200605227B (ru) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9068234B2 (en) * | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
EP2500437B1 (en) * | 2003-01-21 | 2016-11-30 | PTC Therapeutics, Inc. | Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same |
US8426194B2 (en) * | 2003-01-21 | 2013-04-23 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating VEGF expression |
AU2004312411B8 (en) * | 2003-12-31 | 2011-11-24 | Schering-Plough Pty. Limited | Neutralizing epitope-based growth enhancing vaccine |
JP5335239B2 (ja) | 2004-09-30 | 2013-11-06 | マイオスティン・セラピューティクス・プロプライエタリー・リミテッド | ミオスタチンアイソフォーム |
TW200634156A (en) * | 2004-12-30 | 2006-10-01 | Schering Plough Ltd | Neutralizing epitope-based growth enhancing vaccine |
JP5052517B2 (ja) * | 2005-10-06 | 2012-10-17 | イーライ リリー アンド カンパニー | 抗ミオスタチン抗体 |
UA92504C2 (en) * | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
CN101522707B (zh) * | 2006-08-03 | 2013-08-28 | 莫约斯汀医疗有限公司 | 肌肉生长抑制素拮抗剂 |
AU2013231037B2 (en) * | 2006-08-03 | 2016-05-12 | Myostin Therapeutics Pty Ltd | Myostatin antagonists |
EA015916B1 (ru) | 2006-09-05 | 2011-12-30 | Эли Лилли Энд Компани | Моноклональные антитела к миостатину и их применения |
US8283115B1 (en) | 2007-06-20 | 2012-10-09 | Ptc Therapeutics, Inc. | Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation |
US8283116B1 (en) | 2007-06-22 | 2012-10-09 | Ptc Therapeutics, Inc. | Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation |
MX369784B (es) | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
DK2708559T3 (en) | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
UY33421A (es) * | 2010-06-03 | 2011-12-30 | Glaxo Wellcome House | Proteinas de union al antígeno humanizados |
JP2013537425A (ja) | 2010-08-16 | 2013-10-03 | アムジエン・インコーポレーテツド | ミオスタチンに結合するポリペプチド、組成物および方法 |
CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
AU2012339722B2 (en) | 2011-11-14 | 2017-09-14 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A |
EP3597747B1 (en) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
AU2014250434B2 (en) | 2013-04-02 | 2019-08-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
RS61778B1 (sr) | 2013-05-06 | 2021-06-30 | Scholar Rock Inc | Kompozicije i postupci za modulaciju faktora rasta |
TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素a之抗體及其用途 |
CA3005158A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
JP6227191B1 (ja) | 2014-12-19 | 2017-11-08 | 中外製薬株式会社 | 抗ミオスタチン抗体、変異Fc領域を含むポリペプチド、および使用方法 |
KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
MA49661A (fr) | 2015-04-15 | 2020-06-03 | Regeneron Pharma | Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8 |
EP3922645A1 (en) * | 2015-09-15 | 2021-12-15 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
WO2017120523A2 (en) | 2016-01-08 | 2017-07-13 | Scholar Rock, Inc. | Anti-pro/latent myostatin antibodies and methods of use thereof |
SI3368069T1 (sl) | 2016-06-13 | 2021-03-31 | Scholar Rock, Inc. | Uporaba zaviralcev miostatina in kombinirane terapije |
JP6527643B2 (ja) | 2016-08-05 | 2019-06-05 | 中外製薬株式会社 | Il−8関連疾患の治療用又は予防用組成物 |
EP4218817A3 (en) | 2017-01-06 | 2023-09-06 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
CN111787981A (zh) | 2018-03-01 | 2020-10-16 | 瑞泽恩制药公司 | 改变身体组成的方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5977438A (en) | 1988-02-26 | 1999-11-02 | Biosource Technologies, Inc. | Production of peptides in plants as viral coat protein fusions |
CA2014033C (en) * | 1989-04-07 | 1993-02-09 | Stephen D. Acres | Compositions and treatments for pneumonia in animals |
US5422110A (en) * | 1991-10-16 | 1995-06-06 | University Of Saskatchewan | Enhanced immunogenicity using leukotoxin chimeras |
WO1993008290A1 (en) * | 1991-10-16 | 1993-04-29 | University Of Saskatchewan | Enhanced immunogenicity using leukotoxin chimeras |
US5994618A (en) * | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
US20030074680A1 (en) * | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
CA2157577C (en) * | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
US6607884B1 (en) * | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
US6042832A (en) | 1996-08-28 | 2000-03-28 | Thomas Jefferson University | Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins |
AU6274298A (en) | 1997-02-05 | 1998-08-25 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-8 |
AU746643B2 (en) * | 1997-02-05 | 2002-05-02 | Metamorphix International, Inc. | Immunization against endogenous molecules |
US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
GB2333706A (en) * | 1998-02-02 | 1999-08-04 | Merck & Co Inc | Method for increasing muscle mass in animals |
US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
US6004937A (en) * | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
WO1999056768A1 (en) * | 1998-05-06 | 1999-11-11 | Metamorphix, Inc. | Methods for treating diabetes by inhibiting gdf-8 |
US6284882B1 (en) * | 1999-06-10 | 2001-09-04 | Abbott Laboratories | Myostatin gene promoter and inhibition of activation thereof |
KR100750695B1 (ko) * | 1999-07-20 | 2007-08-22 | 파멕사 에이/에스 | Gdf-8 활성을 하향-조절하는 방법 |
EP1072680A1 (en) * | 1999-07-30 | 2001-01-31 | Pfizer Products Inc. | Myostatin regulatory region, nucleotide sequence determination and methods for its use |
CA2385186A1 (en) | 1999-10-13 | 2001-04-19 | Roswell Park Memorial Institute | Induction of a strong immune response to a self-tumor associated antigen |
US6730306B1 (en) * | 2000-03-08 | 2004-05-04 | Large Scale Biology Corporation | Parvovirus vaccine as viral coat protein fusions |
US7037501B2 (en) * | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
WO2004052930A2 (en) | 2002-12-11 | 2004-06-24 | Pharmexa A/S | Targeting single epitopes |
KR101304718B1 (ko) | 2002-12-20 | 2013-09-05 | 암겐 인코포레이티드 | 미오스타틴을 저해하는 결합제 |
AU2004312411B8 (en) * | 2003-12-31 | 2011-11-24 | Schering-Plough Pty. Limited | Neutralizing epitope-based growth enhancing vaccine |
US20060281075A1 (en) * | 2004-12-22 | 2006-12-14 | Large Scale Biology Corporation | Purification of viruses, proteins and nucleic acids |
TW200634156A (en) | 2004-12-30 | 2006-10-01 | Schering Plough Ltd | Neutralizing epitope-based growth enhancing vaccine |
-
2004
- 2004-12-21 AU AU2004312411A patent/AU2004312411B8/en not_active Ceased
- 2004-12-21 CN CNA2004800395458A patent/CN1902221A/zh active Pending
- 2004-12-21 US US11/019,001 patent/US7371726B2/en not_active Expired - Fee Related
- 2004-12-21 EP EP04815235A patent/EP1699820A2/en not_active Withdrawn
- 2004-12-21 CA CA002551877A patent/CA2551877A1/en not_active Abandoned
- 2004-12-21 WO PCT/US2004/043125 patent/WO2005066204A2/en active Application Filing
- 2004-12-21 RU RU2006127314/10A patent/RU2422460C2/ru not_active IP Right Cessation
- 2004-12-21 SG SG200904421-5A patent/SG153874A1/en unknown
- 2004-12-21 UA UAA200608516A patent/UA93855C2/ru unknown
- 2004-12-21 JP JP2006547309A patent/JP2007535912A/ja not_active Withdrawn
- 2004-12-21 BR BRPI0418317-7A patent/BRPI0418317A/pt not_active IP Right Cessation
- 2004-12-21 MX MXPA06007514A patent/MXPA06007514A/es active IP Right Grant
- 2004-12-21 KR KR1020067013214A patent/KR20060120229A/ko active IP Right Grant
- 2004-12-21 NZ NZ547593A patent/NZ547593A/en not_active IP Right Cessation
- 2004-12-22 TW TW093140145A patent/TWI357906B/zh not_active IP Right Cessation
- 2004-12-22 AR ARP040104868A patent/AR047345A1/es active IP Right Grant
-
2005
- 2005-01-03 PE PE2005000029A patent/PE20051050A1/es not_active Application Discontinuation
-
2006
- 2006-06-22 IL IL176494A patent/IL176494A0/en unknown
- 2006-06-23 ZA ZA200605227A patent/ZA200605227B/xx unknown
- 2006-06-29 EC EC2006006683A patent/ECSP066683A/es unknown
- 2006-07-28 NO NO20063478A patent/NO20063478L/no not_active Application Discontinuation
-
2008
- 2008-04-02 US US12/061,012 patent/US7585648B2/en not_active Expired - Fee Related
-
2009
- 2009-08-04 US US12/535,298 patent/US7892561B2/en not_active Expired - Fee Related
-
2011
- 2011-01-20 JP JP2011010279A patent/JP2011083290A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BRPI0418317A (pt) | 2007-05-02 |
CA2551877A1 (en) | 2005-07-21 |
AU2004312411B2 (en) | 2011-11-03 |
NZ547593A (en) | 2009-09-25 |
MXPA06007514A (es) | 2006-08-31 |
US20080227156A1 (en) | 2008-09-18 |
CN1902221A (zh) | 2007-01-24 |
ECSP066683A (es) | 2006-10-25 |
UA93855C2 (ru) | 2011-03-25 |
IL176494A0 (en) | 2006-10-05 |
RU2422460C2 (ru) | 2011-06-27 |
NO20063478L (no) | 2006-08-28 |
TW200526683A (en) | 2005-08-16 |
JP2007535912A (ja) | 2007-12-13 |
WO2005066204A2 (en) | 2005-07-21 |
WO2005066204A3 (en) | 2005-08-11 |
KR20060120229A (ko) | 2006-11-24 |
AU2004312411B8 (en) | 2011-11-24 |
US20050143306A1 (en) | 2005-06-30 |
US20090311282A1 (en) | 2009-12-17 |
US7892561B2 (en) | 2011-02-22 |
US7585648B2 (en) | 2009-09-08 |
EP1699820A2 (en) | 2006-09-13 |
AU2004312411A1 (en) | 2005-07-21 |
AR047345A1 (es) | 2006-01-18 |
PE20051050A1 (es) | 2005-12-12 |
RU2006127314A (ru) | 2008-02-10 |
TWI357906B (en) | 2012-02-11 |
ZA200605227B (en) | 2007-03-28 |
US7371726B2 (en) | 2008-05-13 |
JP2011083290A (ja) | 2011-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG153874A1 (en) | Neutralizing epitope-based growth enhancing vaccine | |
CY1121353T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
CY1122505T1 (el) | Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn | |
WO2002080851A3 (en) | Chimeric vaccines | |
IL189313A0 (en) | Virus-like particles as vaccines for paramyxovirus | |
ATE474048T1 (de) | Her2/neu fusionsproteine | |
DK1355930T3 (da) | Fremgangsmåde til identifikation, isolering og fremstilling af antigener mod et specifikt patogen | |
NZ577828A (en) | Human antibodies that bind human il-12 and methods for producing | |
NZ591415A (en) | Haemophilus influenzae type B | |
DE60310562D1 (de) | Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen | |
WO2005007673A3 (en) | Immunogenic peptides | |
ATE551069T1 (de) | Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung | |
GB0113798D0 (en) | Antigens and vectors for vaccination | |
GB0118532D0 (en) | Materials and methods relating to improved vaccination strategies | |
TW200634156A (en) | Neutralizing epitope-based growth enhancing vaccine | |
ATE417112T1 (de) | Steigerung der immunantwort unter verwendung von zielgerichteten molekülen | |
ZA200602107B (en) | Piroplasmid vaccine | |
ATE269905T1 (de) | Verfahren zur herstellung von proteinen in wirtszellen unter verwendung von chaperoninen | |
GB0409559D0 (en) | Polypeptide | |
WO2004053061A8 (en) | Methods of therapy and diagnosis using targeting of cells that express lax | |
ATE419350T1 (de) | Humanes trp-ähnliches kalziumkanalprotein-2 tlcc- 2 | |
ATE450546T1 (de) | Impfstoffe mit ornithobakterium rhinotracheale- untereinheit | |
WO2004024769A3 (en) | Ostertagia vaccine | |
ATE346926T1 (de) | Menschliche twik-8 moleküle und ihre verwendung | |
WO2004047612A3 (en) | Methods of therapy and diagnosis |